Drug-induced valvular heart disease

Article written and reviewed by Dr Luca Moretti

Drug-induced valvular heart disease is an acquired disease in which a biologically plausible drug exposure contributes to thickening, retraction and dysfunction of one or more heart valves. The paradigm is non-inflammatory fibrosis mediated mainly by agonism of serotonergic 5-HT2B receptors: the valvular tissue retains its basic architecture but becomes coated and deformed by extracellular matrix and myofibroblastic cells. The predominant result is regurgitation, sometimes associated with stenosis, multivalvular involvement and progressive cardiac chamber overload.

The entity does not include every valvular disorder that appears during drug therapy. A patient treated with a medication may independently develop calcific degeneration, prolapse, endocarditis or functional regurgitation; conversely, the responsible exposure may be remote and absent from the current medication list. Diagnosis therefore requires a relationship built on the substance involved, cumulative dose, duration, latency, echocardiographic morphology and the absence of a more convincing alternative explanation.

The history of this disease is also a history of pharmacovigilance. Anorectic agents and ergot derivatives were withdrawn or severely restricted after clinical reports, case-control studies and cohort studies documented associations consistent with their receptor profiles. Experience has shown that a rare but serious effect may become apparent only after widespread exposure and that mild Doppler regurgitation must not be confused with morphologically induced valvular heart disease.

Management requires coordination among the cardiologist, prescribing specialist, general practitioner and, when necessary, clinical pharmacologist. The decision is not simply whether to continue or discontinue the drug: the benefit of treatment, availability of alternatives, severity of the lesion and probability that the exposure truly contributed to it must all be balanced. Unsupervised discontinuation of essential treatment may be harmful, but continuing therapy without reconstructing cumulative risk may also promote consolidation of fibrosis.

Implicated drugs, cumulative dose and strength of the causal relationship

The historically strongest associations involve fenfluramine and dexfenfluramine, used as anorectic agents, and benfluorex, a fenfluramine derivative used in some countries for diabetes and dyslipidemia. Initial reports of aortic and mitral regurgitation after fenfluramine-phentermine were followed by epidemiological and pathological studies. Phentermine does not share the same potent 5-HT2B activity, and the risk associated with the combination does not justify automatically attributing independent causality to phentermine.

Benfluorex, which is metabolized to norfenfluramine, a 5-HT2B agonist, is one of the best-documented examples. French studies associated exposure with unexplained mitral or aortic regurgitation and with hospitalization or valve surgery, showing a relationship compatible with cumulative dose. Because the deformation may become clinically evident even after discontinuation, the history must reconstruct remote prescriptions: a drug withdrawn from the market may remain relevant many years after the last dose.

Pergolide and cabergoline are ergot-derived dopamine agonists that also have 5-HT2B activity. In patients with Parkinson disease, who received high daily and cumulative doses, studies published in 2007 documented more clinically important regurgitation than in controls and in patients receiving non-ergot agonists. Pergolide was withdrawn from several markets; cabergoline continues to be used mainly in endocrinology at much lower weekly doses.

The distinction between neurological and endocrine use is essential. In hyperprolactinemia, most cohorts have not demonstrated a convincing excess of morphologically typical valvular heart disease at the usual low doses, although studies are limited by sample size, duration and statistical power for rare events. An increase in trivial or mild regurgitation without thickening and retraction is not equivalent to cabergoline-associated valvular heart disease. A dose above 2 mg/week, prolonged exposure or suspicious findings nevertheless justify more intensive surveillance.

Methysergide and ergotamine, historically used for migraine, belong to the spectrum of fibrogenic ergot derivatives and may also be associated with retroperitoneal, pleuropulmonary or pericardial fibrosis. Exposure is less common today, but recognition remains relevant in older patients or in countries with different patterns of availability. A history of multiple fibrosing syndromes in the same patient strengthens suspicion without replacing morphological assessment of the valve.

3,4-methylenedioxymethamphetamine, known as MDMA or ecstasy, has serotonergic activity and has been associated in small series with regurgitation and compatible morphology. The evidence is much less robust than for fenfluramine, benfluorex and ergot agonists because the actual dose, adulterants and co-exposures are difficult to measure. A history of recreational substance use should be obtained nonjudgmentally, but the finding should not be presented as certain proof of causality.

Not all drugs that increase synaptic serotonin share the same valvular risk. The key determinant is direct agonism, or agonism mediated by metabolites, at the 5-HT2B receptor, rather than simple membership in the category of “serotonergic” drugs. Selective serotonin reuptake inhibitors, for example, have not shown a comparable causal signal and do not require routine valvular echocardiography for this reason alone; confusing different mechanisms instead leads to alarm and inappropriate discontinuation.

The strength of the causal relationship increases when recognized exposure, sufficient cumulative burden, involvement of multiple valves and characteristic fibrosing morphology coexist. It decreases when the lesion predates treatment, when age-related calcification or commissural fusion predominates, or when regurgitation is explained by ventricular or atrial dilation. No blood test can attribute the etiology to a drug: diagnosis remains clinical, history-based and imaging-based.

5-HT2B receptor, interstitial cells and pathological anatomy

5-HT2B receptors are expressed on valvular interstitial cells and participate in regulation of growth and extracellular matrix. Persistent stimulation activates mitogenic and profibrotic pathways, promoting myofibroblastic transformation and the production of collagen, glycosaminoglycans and growth factors. 5-HT2B agonism is a necessary and strongly predictive property for many classic valvulopathic agents, although host susceptibility, pharmacokinetics and duration modulate the individual outcome.

Norfenfluramine illustrates the role of metabolites: the administered molecule and the products of its metabolism may have different receptor profiles. Cabergoline and pergolide combine therapeutic dopaminergic activity with unwanted serotonergic agonism; pramipexole and ropinirole, which are not ergot derivatives, do not share the same potent activity. Classification by clinical indication is therefore less informative than receptor pharmacology.

Macroscopically, the leaflets appear smooth, whitish, thickened and retracted. Plaques coat the valvular surfaces and subvalvular apparatus without suppurative destruction, perforation or the vegetations typical of endocarditis. Histologically, myofibroblasts are seen within a collagenous and mucopolysaccharide matrix over relatively preserved architecture, with inflammation and neovascularization generally less prominent than in rheumatic heart disease.

The resemblance to carcinoid heart disease is not coincidental, because both converge on serotonergic signaling and a fibrosing response. In carcinoid disease, the tricuspid and pulmonary valves often predominate because mediators reach the right heart; with circulating drugs, the aortic and mitral valves are frequently affected, although all valves may be involved. Distribution and clinical context are helpful without constituting an absolute rule.

Retraction reduces the coaptation surface and mainly causes regurgitation; when thickening and stiffness also limit opening, a stenotic component may develop, generally less important than loss of valve competence. In the mitral valve, the chordae may shorten and partially fuse, whereas the aortic cusps may become stiff and fail to coapt. The absence of marked commissural fusion and predominant calcification often helps distinguish this phenotype from rheumatic or degenerative disease.

The lesion may continue to become manifest after the drug has been eliminated, because the problem is not a persistent circulating concentration but the deposited matrix. After discontinuation, cellular signaling may decrease and some mild regurgitation may improve; a severely retracted valve does not necessarily recover. Biological stabilization and anatomical normalization are not synonymous, and follow-up must assess both.

No universal dose threshold has been defined that can separate safety from toxicity for every substance. Observational studies show risk gradients, but prescriptions, adherence and susceptibility vary. The cumulative dose should be calculated whenever possible from average dose, frequency and duration, documenting interruptions and uncertainty; a crudely reconstructed figure should not be turned into a diagnostic cutoff.

Valvular heart disease is only one possible manifestation of drug-induced fibrosis. Pleuritis, effusions, pericardial thickening, pulmonary fibrosis or retroperitoneal fibrosis may modify symptoms and operative risk. Dyspnea and edema should not automatically be attributed to the severity of regurgitation: hemodynamic overload, pulmonary restriction, pericardial constriction and other treatment toxicities must be distinguished.

Echocardiographic phenotype and differential diagnosis

Transthoracic echocardiography is the initial examination and should systematically assess all four valves, not only the valve responsible for the murmur. Thickness, mobility, retraction, coaptation, the subvalvular apparatus and the annulus define morphology, whereas color Doppler and spectral Doppler quantify stenosis and regurgitation using a multiparametric approach. Chamber dimensions, ventricular function and pulmonary pressure show the hemodynamic consequences; acquiring standardized images also makes longitudinal comparison more reliable.

The most suggestive finding is diffuse restriction with thickened and retracted leaflets or cusps, associated with regurgitation disproportionate to calcification, prolapse or annular dilation. In the mitral valve, systolic restriction may predominate without the typical rheumatic doming; in the aortic valve, an incomplete line of coaptation produces regurgitation. The tricuspid valve may appear fixed in a semi-open position. No single sign, however, has sufficient sensitivity and specificity to establish the etiology.

The severity of regurgitation is graded according to contemporary criteria for the native valve, integrating vena contracta, flow convergence, Doppler density and profile, venous flows, volumes and remodeling. An eccentric jet may be underestimated by color Doppler; multiple jets make a single measurement less reliable. Classification should not use historical pharmacovigilance thresholds, developed to identify population signals, as automatic equivalents of clinically severe regurgitation.

Transesophageal echocardiography, especially three-dimensional imaging, clarifies coaptation and the valvular apparatus when transthoracic imaging is limited or when an intervention is being planned. Cardiac magnetic resonance imaging quantifies ventricular volumes and regurgitant fraction in discordant cases; computed tomography demonstrates calcification and preoperative anatomy but does not by itself identify the drug-related nature of the fibrosis. Multimodality imaging resolves a mechanical question; it does not replace the history.

The differential diagnosis with rheumatic heart disease considers epidemiological history, commissural fusion, doming and marked chordal involvement. Myxomatous degeneration produces excessive motion or flail rather than the typical diffuse retraction; degenerative calcification is concentrated on the aortic cusps or mitral annulus. Radiation-induced valvular heart disease often involves the aortic root and aorto-mitral continuity with extensive calcification.

Carcinoid disease should be investigated when flushing, diarrhea, bronchospasm, liver metastases or predominantly right-sided disease are present, using the appropriate neuroendocrine workup. Endocarditis is considered in the presence of fever, positive blood cultures, vegetations, perforation or new dehiscence; a smooth plaque is not a vegetation. Functional regurgitation requires altered ventricular or atrial geometry and leaflets that are not primarily fibrotic, although an organic component may coexist.

The medication history should cover weight-loss drugs, antiparkinsonian agents, endocrine therapies, antimigraine drugs and recreational substances, specifying historical brand names and the country in which they were prescribed. The interval between exposure and symptoms, weekly or daily dose, duration, reasons for discontinuation and previous echocardiographic reports should be sought. A current “negative” medication list does not exclude an exposure that ended fifteen years earlier.

The report should distinguish “valvular regurgitation” from “morphology compatible with drug-induced valvular heart disease.” The latter wording requires structural abnormalities and comparison with baseline. Minimal physiological regurgitation is common, especially on the right side, and may vary with the machine, loading conditions and observer. Labeling it as toxicity creates unjustified permanent diagnoses and may deprive the patient of effective therapy.

The final probability may be expressed as certain, probable, possible or unlikely only after multidisciplinary integration. Surgical specimens may confirm compatible fibrosis but rarely identify the specific drug. The causal relationship remains strongest when the pathology is coherent, the exposure is recognized and no other cause emerges; routine biopsy is not indicated for a valve that does not already require intervention.

Surveillance during cabergoline and other exposures

There is no single echocardiographic program for all potentially serotonergic drugs. Surveillance should reflect the level of evidence, planned dose, duration and recommendations for the specific indication. Before high-risk therapy, it is reasonable to document the history, cardiac examination and a baseline echocardiogram when recommended; for many substances without a valvulopathic signal, indiscriminate screening is not justified.

For cabergoline in hyperprolactinemia, a joint British position statement recommends echocardiography before treatment. If the total dose is no greater than 2 mg/week, it suggests follow-up at five years and, if unchanged, every five years thereafter; above 2 mg/week, it recommends annual assessment. Symptoms, a new murmur or a morphological change always warrant earlier examination. These are scientific-society recommendations, not randomized evidence or an immutable universal protocol.

A baseline study prevents pre-existing thickening or regurgitation from being attributed to treatment. It should include images of the right-sided valves, often omitted in older studies, and a morphological description in addition to the grade of regurgitation. If follow-up shows an isolated increase from trace to mild regurgitation without retraction, the first action is expert review of the images and loading conditions, not automatic discontinuation.

When compatible abnormalities emerge, the cardiologist compares studies side by side and the prescribing specialist reassesses the minimum effective dose, alternatives and clinical need. The position statement recommends that decisions to discontinue treatment be made after review by an expert echocardiographer. This caution is particularly important in prolactinoma, where hormonal control protects against neurological, gonadal and skeletal consequences.

In patients previously exposed to fenfluramine or benfluorex, there is no permanent surveillance interval applicable to everyone. The appearance of a murmur, dyspnea, functional decline or signs of congestion is an indication for echocardiography, whereas a previously documented lesion is followed according to severity and trajectory. A normal examination many years after exposure reduces the likelihood of important valvular disease but does not replace clinical assessment if new symptoms develop.

Clinical pharmacovigilance requires suspected adverse reactions to be reported through the national system, including dose, latency, imaging and alternative diagnoses. A single report does not prove causality, but coherent series may identify a signal before epidemiological studies become available. Descriptive accuracy is crucial: “mild mitral regurgitation” and “progressive multivalvular mitral retraction” have very different safety implications.

Developers of new drugs assess 5-HT2B activity in secondary pharmacology panels, but an in vitro test does not directly translate into concentration, metabolism and clinical risk. The absence of relevant agonism lowers suspicion; its presence requires more detailed study. The most effective prevention remains avoiding unnecessary exposure to valvulopathic agents and, when their use is indispensable, using the minimum dose and appropriate duration.

Pregnancy, advanced age, renal or hepatic impairment and polypharmacy alter pharmacokinetics and hemodynamic tolerance, but there are no validated coefficients with which to adjust valvular risk. Known valvular heart disease requires specific pregnancy planning; endocrine therapy is coordinated with the endocrinologist and Pregnancy Heart Team when the lesion is significant. The aim is not to generate indefinite serial testing, but to recognize clinically meaningful progression.

Discontinuation, valve treatment and prognosis

When the causal relationship is plausible, the first etiological intervention is to reduce or discontinue exposure, always in agreement with the physician managing the underlying condition. A possible alternative without valvulopathic activity, dose reduction and the consequences of less effective control of the treated disease should be considered. For non-therapeutic exposures, the pathway should also include addiction treatment and harm-reduction measures, rather than a simple recommendation to stop.

After discontinuation, a comparable echocardiogram documents stability, regression or progression. Studies of anorectic agents have observed attenuation of regurgitation in some patients, but the findings do not permit a promise of individual recovery. Established fibrosis may remain hemodynamically important; subsequent progression requires reassessment of other causes, loading conditions, measurement error and unrecognized persistence of exposure.

Diuretics treat congestion, while blood pressure control and heart failure therapy reduce ventricular load when indicated, but no antifibrotic drug has been shown to restore the leaflets. Anticoagulants and antiplatelet agents do not prevent this form of valvular disease in the absence of an independent indication. Medical management follows the ventricular phenotype, rhythm and affected valve, avoiding confusion between treatment of consequences and etiological cure.

Indications for intervention are those for the corresponding native-valve lesion, integrated with symptoms, ventricular function, pulmonary pressure, procedural risk and life expectancy. A drug-related cause does not automatically bring surgery forward, but multivalvular involvement may create a greater burden than any single measurement suggests. The Heart Team should know whether exposure has ceased and whether pulmonary, pericardial or retroperitoneal fibrosis coexists and increases complexity.

Repair is technically difficult when leaflets and chordae are diffusely retracted and mobile tissue is lacking. It may be appropriate in focal anatomies, whereas replacement becomes more predictable in advanced fibrosing disease. Prosthesis type and access are selected according to age, anticoagulation, anatomy and the possibility of future procedures; there is no prosthesis specific to a drug-related cause.

A transcatheter procedure may be considered according to valve-specific recommendations and surgical risk, but there are no trials dedicated to drug-induced valvular heart disease. Multivalvular retraction, a small orifice or rigid tissue may limit edge-to-edge repair; TAVI treats selected aortic stenosis or regurgitation, not the systemic fibrotic process. Anatomical feasibility does not necessarily imply clinical benefit.

Prognosis depends on severity at recognition, the number of affected valves, ventricular function and the possibility of eliminating the cause. A mild lesion that remains stable after discontinuation may be asymptomatic for years; severe regurgitation with pulmonary hypertension or right ventricular dysfunction carries a different risk. Follow-up is calibrated to the most important lesion and becomes more frequent if symptoms, remodeling or Doppler changes appear.

Prevention depends above all on clinical memory. Asking only which medications the patient currently takes will not identify withdrawn anorectic agents, previous antiparkinsonian therapies or recreational exposures; it is more useful to reconstruct treatments by indication and historical period. In this way, a well-founded diagnosis can protect against further exposure without attributing every incidental finding to a drug, preserving both pharmacovigilance and cardiological rigor.